Kanada - angleščina - Health Canada

biogen canada inc - interferon beta-1a - solution - 30mcg - interferon beta-1a 30mcg - immunomodulatory agents

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - interferon beta-1b - powder and solvent for solution for injection - 300microgram

Združene države Amerike - angleščina - NLM (National Library of Medicine)

genentech, inc. - peginterferon alfa-2a (unii: q46947fe7k) (peginterferon alfa-2a - unii:q46947fe7k) - peginterferon alfa-2a 180 ug in 1 ml - adult patients: pegasys, as part of a combination regimen with other hepatitis c virus (hcv) antiviral drugs, is indicated for the treatment of adults with chc and compensated liver disease. for information about the safe and effective use of other hcv antiviral drugs to be used in combination with pegasys, refer to their prescribing information. pegasys monotherapy is only indicated for the treatment of patients with chc and compensated liver disease if there are contraindications or significant intolerance to other hcv antiviral drugs. pediatric patients: pegasys in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with chc and compensated liver disease. limitations of use : - pegasys alone or in combination with ribavirin without additional hcv antiviral drugs is not recommended for treatment of patients with chc who previously failed therapy with an interferon-alfa. - pegasys is not recommended for treatment of patients with chc who have had solid

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 250microgram/1ml

Singapur - angleščina - HSA (Health Sciences Authority)

merck pte. ltd. - interferon beta-1a - injection, solution - 22mcg/0.5ml - interferon beta-1a 22mcg/0.5ml

Singapur - angleščina - HSA (Health Sciences Authority)

merck pte. ltd. - interferon beta-1a - injection, solution - 44mcg/0.5ml - interferon beta-1a 44mcg/0.5ml

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - interferon beta-1a, quantity: 60 microgram/ml - injection, solution - excipient ingredients: polysorbate 20; glacial acetic acid; sodium acetate; water for injections; arginine hydrochloride - avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis (ms). avonex is indicated in patients who have experienced a single demyelinating event and are at risk of developing clinically definite ms based on the presence of brain mri abnormalities characteristic of ms. avonex 60 mcg is indicated for the treatment of secondary progressive ms in patients in whom relapse is still a feature of disease. avonex 60 mcg should not be initiated in patients with secondary progressive ms who have not experienced relapse in the previous 12 months.

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

12million units - interferon beta-1a - solution for injection - 24mega u/1ml

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

6million units - interferon beta-1a - solution for injection - 12mega u/1ml

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

6million units - interferon beta-1a - solution for injection - 12mega u/1ml